Hydroxysafflor yellow A attenuates high glucose-induced human umbilical vein endothelial cell dysfunction

Abstract

High glucose (HG) induces vascular injury in diabetes. Hydroxysafflor yellow A (HSYA) has been used to ameliorate ischemic cardiovascular diseases in China for many years. In the present study, we assessed whether HSYA has a potential protective role in HG-induced human umbilical vein endothelial cell (HUVEC) injury. Cell viability was determined with an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Cell apoptosis was detected by fluorescein isothiocyanate/propidium iodide staining assay. The endothelial cell permeability was measured with a permeability assay. Cell adhesion molecule (CAM) expression, vascular endothelial growth factor, and basic fibroblast growth factor levels were detected with an enzyme-linked immunosorbent assay. Reactive oxygen species (ROS) formation was measured with a DCF-DA assay. Protein expression of NADPH oxidase 4 (NOX4) was measured by Western blotting. Our data indicated that HG increases HUVEC apoptosis, vascular permeability, monocyte adhesion, the level of CAMs, the formation of ROS, and NOX4 expression. Our data revealed that HG increases vascular injury, which is attenuated by HSYA. Because vascular inflammation has a key role in the development of diabetes mellitus, our results implied that HSYA is considered as a potential agent for diabetic vascular injury treatment.

Keywords

Hydroxysafflor yellow A high glucose diabetes mellitus human umbilical vein endothelial cells NOX4

Introduction

Both obesity and physically inactive lifestyles are related to increases in the incidence of diabetes mellitus (DM), which is a major global health burden.^1,2 Diabetic vascular disease is one of the leading causes of death worldwide.^3,4 Extensive investigation has reported that DM impairs endothelial function via reducing vasodilatation and inhibiting endothelial cell (EC) repairs.^5,6 Previous studies have indicated that high glucose (HG) stimulates excessive reactive oxygen species (ROS) generation in many kinds of cells.^7
–9 Then, overexpression of ROS enhances cell dysfunction and apoptosis.^10,11 Thus, suppression of oxidative stress is considered as a potential strategy for DM.¹² It is important to find new therapy for treating HG-induced endothelial cell (EC) injury.

There are many studies that have demonstrated that hydroxysafflor yellow A (HSYA) has anti-inflammatory,¹³ antioxidative,¹⁴ and antiangiogenic functions both in vitro and in vivo.¹⁵ HSYA is a key water-soluble compound of safflor yellow with a chalcone glycoside structure. HSYA has been isolated from Carthamus tinctorius¹⁶ and is known as one of the standard elements for Carthami Flos quality control following the Chinese Pharmacopoeia, due to its high activity. HSYA has been applied widely to treat several diseases, including cardiovascular^17,18 and cerebrovascular diseases.¹⁹ HSYA prevents oxidative stress generation, the inflammatory response, and cell apoptosis in spinal cord injury (SCI) rats, suggesting that HSYA may be a neuroprotective agent for SCI.²⁰ HSYA also suppresses idiopathic pulmonary fibrosis development via delaying lung fibroblast proliferation, migration, and differentiation.²¹ In addition, HSYA reduces hepatocellular carcinoma (HCC) proliferation and metastasis via inhibiting angiogenesis.²² However, the molecular mechanisms underlying HSYA protecting ECs remain largely unknown.

In this study, we aimed to investigate the potential effects of HSYA on HG-induced human umbilical vein endothelial cell (HUVEC) injury as well as the underlying mechanisms.

Materials and methods

Chemicals and reagents

Glucose was purchased from Sigma-Aldrich (St Louis, Missouri, USA). HSYA standards were obtained from China Pharmaceutical and Biological Products (Beijing, China). All antibodies, including primary and horseradish peroxidase-conjugated secondary antibodies, were purchased from Sigma-Aldrich.

Cell culture and treatment

HUVECs were purchased from American Type Culture Collection (ATCC), and cells were seeded in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% carbon dioxide at 37°C.

The human monocytic cell lines THP-1 were purchased from ATCC and cultured in RPMI 1640 medium (Thermo Fisher Scientific) with 10% FBS, penicillin (100 units/ml), streptomycin (100 ng/ml), and 50 µM 2-ME (Fisher Scientific, Pittsburgh, Pennsylvania, USA) at 37°C in air atmosphere.

Cell viability

Cell viability was determined with a Cell Titer 96TM AQueous cell viability assay kit (MTS, Promega, Promega Corporation, Madison, WI). HUVECs (5 × 10³ cells/well) were seeded in 96-well culture plates overnight. After the cells were treated with HSYA (0–50 μM) and glucose (50 μM) for 24 h, 20 μL CellTiter 96 Aqueous One Solution Reagent was added for 1 h at 37°C. The optical density (OD) was measured at 490 nm by a microplate reader (BioTek, Winooski, Vermont, USA).

Annexin-V/FITC assay

The apoptosis of HUVECs was quantified by an Annexin-V/fluorescein isothiocyanate (FITC) apoptosis assay kit (BD Biosciences, San Jose, California, USA) following the manufacturer’s instructions. The percentage of apoptotic cells was measured with a flow cytometer (BD, Minneapolis, MN, USA).

Permeability assay

The EC permeability was quantified by the flux of Evans blue-bound albumin across functional cell monolayers as previously described. HUVECs (5 × 10⁴ cells/well) were seeded in a transwell for 24 h. Then, 0.5 mL of Evans blue solution was added to the upper chamber. The RPMI 1640 medium with 10% FBS was added to the lower chamber for 30 min. The OD of the lower chamber was evaluated at 650 nm with a microplate reader (BioTek).

Levels of CAMs with an ELISA

The levels of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin were detected with an enzyme-linked immunosorbent assay (ELISA) (Sigma-Aldrich). Briefly, cells were treated with HSYA (0–50 μM) and glucose (50 μM) for 24 h and fixed in 1% paraformaldehyde. The mouse antihuman monoclonal antibodies were incubated for 1 h. Then, cells were washed with phosphate-buffered saline (PBS), treated with peroxidase-conjugated anti-mouse immunoglobulin G antibodies for 1 h, and the o-phenylenediamine substrate was added. All measurements were performed in triplicate.

HUVEC adhesion assay

The adherence of monocytes to ECs was detected by fluorescent labeling of monocytes, as previously described.²³ Monocytes were labeled with fluorescence-labeled using Calcein-AM (100 μM, R&D Systems). The monocytes and HUVECs were coincubated for 30 min at 37°C in air atmosphere. Nonadherent cells were washed with PBS. The OD was assessed at 492 nm (excitation) and 535 nm (emission) with a microplate reader (BioTek).

H₂O₂ release assay

The extracellular generation of hydrogen peroxide (H₂O₂) was tested with an Amplex Red Hydrogen Peroxide Assay Kit (Molecular Probes, Eugene, Oregon, USA) following the manufacturer’s protocol. Cells were resuspended in a Krebs–Ringer phosphate–glucose (KRPG) solution. The reaction mixture (100 μL, 50 μM Amplex Red reagent with 0.1 U/mL HRP in KRPG) was incubated at 37°C for 10 min. Then, KRPG solution (20 μL) was added to the cells for 30 min. The OD was assessed at 560 nm with a microplate reader (BioTek).

Intracellular ROS assay

The DCF-DA assay was used to measure the level of ROS. HUVECs were incubated with 2′,7′-dichloro dihydroflourescein diacetate (DCFH-DA) (10 μM) for 30 min at 37°C. The OD was evaluated at 485 nm (excitation) and 535 nm (emission) with a microplate reader (BioTek).

Western blotting

The total proteins were lysed using radioimmunoprecipitation assay (RIPA) buffer mixed with a protease inhibitor cocktail (Thermo Scientific, Rockford, Illinois, USA). The protein concentration was measured with a bicinchoninic acid assay (BCA) protein assay kit. Then, 30 µg of protein was separated with sodium dodecyl sulfate–polyacrylamide gel electrophoresis (10%) and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, Massachusetts, USA). The PVDF membranes were blocked with 5% nonfat milk for 1 h at room temperature. Then, the primary antibodies (anti-NOX4) were added to the membranes overnight at 4°C. The membranes were incubated with the secondary antibodies for 1 h at 37°C. Finally, the membranes were detected with an ECL reagent system (Thermo Scientific). The bands were analyzed with ImageJ Software (NIH, Bethesda, Maryland, USA).

VEGF and bFGF content in the cell culture supernatant by ELISA

The VEGF and bFGF levels were measured using a human VEGF ELISA kit (Thermo Fisher Scientific) and human bFGF ELISA kit (Thermo Fisher Scientific) following the manufacturer’s instructions. The OD was evaluated at 450 nm and 492 nm with a microplate reader (BioTek).

Statistical analysis

All measurements were performed in triplicate. All data were analyzed with SPSS 21.0 statistical software (SPSS, Inc., Chicago, Illinois, USA). The results are given as the mean ±standard deviation. Statistical significance was determined using a one-way analysis of variance. A p-value ≤0.05 was considered statistically significant.

Results

The effects of HSYA on HUVEC viability

To avoid possible effects of HSYA on HUVEC viability, cell viability was assessed with an MTS assay. The data indicated that HSYA had no effect on cell viability at a concentration of 50 µM (Figure 1(a)) for 72 h (Figure 1(b)). Therefore, a 50 µM concentration was used in all subsequent experiments.

Figure 1.

Effect of HSYA and HG on the cell viability of HUVECs. (a) HUVECs were treated with different concentrations of HSYA (0–50 µM) for 24 h. Cell viability (OD490) was assessed with a MTS assay. (b) HUVECs were treated with different concentrations of HSYA (50 µM) for 0–72 h, and cell viability (OD490) was assessed with an MTS assay. (c) HUVECs were cultured with control or HG medium in the absence or presence of HSYA (50 µM), and cell viability was measured with an MTS assay. *p < 0.05 versus control group; ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell; OD: optical density.

Compared with the control group, HUVEC viability in the HG group was decreased (p < 0.05, Figure 1(c)). HSYA-induced HUVEC viability was compared with the HG group for 24 h (p < 0.05, Figure 1(c)).

HSYA attenuates HG-induced HUVEC apoptosis

The percentages of apoptotic cells were quantified with an FITC/ propidium iodide (PI) and flow cytometer assay. After the cells were incubated with HG for 24 h, the rates of apoptotic cells were increased. This incremental apoptosis was reduced when the cells were treated with HSYA. Therefore, HSYA-reduced HUVEC apoptosis was compared with the HG group (Figure 2).

Figure 2.

(a) HSYA reverses HG-induced HUVEC apoptosis. HUVECs were treated with HSYA (50 µM) and HG for 24 h, and (b) the rate of apoptosis in HUVECs was detected using an FITC/PI assay. The experiment was repeated at least three times. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell.

Effects of HSYA on HG-induced disruption of the endothelial barrier function in HUVECs

To investigate the effects of HG on EC permeability, a permeability assay was used. HG-induced EC permeability was monitored for 24 h (Figure 3(a)).

Figure 3.

Effects of HSYA on HG-induced HUVEC permeability changes. (a) HUVECs were treated with HG for 24 h, and permeability was monitored. (b) HUVECs were treated with HSYA for 24 h, and permeability was monitored. (c) HUVECs were treated with HSYA and HG for 24 h, and permeability was monitored. The experiment was repeated at least three times. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell.

Next, we examined whether HSYA can alter HG-induced membrane disruption. HSYA (50 μM) did not alter the barrier integrity (Figure 3(b)). As shown in Figure 3(c), treatment with HSYA led to a decrease in HG-enhanced hyperpermeability.

Effects of HSYA on HG-enhanced CAM expression and THP-1 adhesion

To determine the effects of HG on the expression of CAM, an ELISA was used. HG resulted in an increase in CAM expression, including VCAM-1, ICAM-1, and E-selectin (Figure 4(a)). Further, inhibition of CAM expression was exhibited when HUVECs were treated with HSYA (Figure 4(a)).

Figure 4.

Effects of HSYA on HG-induced inflammatory responses. (a) HG-induced CAM expression in HUVECs was determined. VCAM-1, ICAM-1, and E-selectin were detected with an ELISA. (b) The amounts of adherent human neutrophils were observed with a cell–cell adhesion assay. The experiment was repeated at least three times. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell; VCAM-1: vascular cell adhesion molecule-1; ICAM-1: intercellular adhesion molecule-1; CAM: cell adhesion molecule; ELISA: enzyme-linked immunosorbent assay.

To assess the effect of HSYA on the adhesion of monocytes to HUVECs, we detected the adhesion of THP-1 cells to HUVECs. Compared with the control group, HG enhanced adhesion ability. Treatment with HSYA led to a decrease in the adhesion of THP-1 cells to HG-induced HUVECs (Figure 4(b)).

Effects of HSYA on the level of VEGF and bFGF in the HG-treated HUVECs

Compared with the control group, the levels of VEGF (Figure 5(a)) and bFGF (Figure 5(b)) were enhanced in the HG group. Compared with the HG group, the levels of VEGF (Figure 5(a)) and bFGF (Figure 5(b)) in the HG + HSYA group were reduced.

Figure 5.

HSYA reverses the HG-increased levels of VEGF and bFGF in HUVECs. (a) VEGF levels in HUVECs were determined using an ELISA. (b) bFGF levels in HUVECs were determined with an ELISA. The experiment was repeated at least three times. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell; VCAM-1: vascular cell adhesion molecule-1; ICAM-1: intercellular adhesion molecule-1; CAM: cell adhesion molecule; ELISA: enzyme-linked immunosorbent assay.

Effect of HSYA on HG-induced oxidative stress

The H₂O₂ (Figure 6(a)) and ROS (Figure 6(b)) levels showed an increase after treatment with HG. However, HSYA had no effect on HUVEC oxidative stress, including H₂O₂ (Figure 6(a)) and ROS levels (Figure 6(b)). As shown in Figure 6, HSYA (50 μM) resulted in a suppression of HG-induced H₂O₂ and ROS levels.

Figure 6.

Effects of HSYA on HG-induced H₂O₂ and ROS formation. Cells were treated with HSYA and HG for 24 h. (a) The production of H₂O₂ was detected with a H₂O₂ release assay. (b) The production of ROS was detected by DCFH-DA staining. The experiment was repeated at least three times. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell; ROS: reactive oxygen species; H₂O₂: hydrogen peroxide.

Effect of HG-induced ROS production by activating NOX4

Our data indicated that ROS levels were enhanced in HG-treated HUVECs. To determine the role of NOX on HG-induced oxidative stress, the NOX inhibitor DPI (2.5 μmol/L) was used. As shown in Figure 7(a), DPI decreased the level of ROS in response to HG. FITC/PI assays also showed that HUVEC apoptosis was reduced by DPI (Figure 7(b)).

Figure 7.

HSYA decreases HG-induced ROS generation and apoptosis in HUVECs through the NOX4 pathway. (a) DPI-decreased ROS production in HUVECs induced by HG. (b) DPI decreased the apoptosis rate in HG-treated HUVECs. (c) HSYA-decreased HG-induced NOX4 expression. Data are shown as the mean ± SD of three experiments. *p < 0.05 versus control group. ^#p < 0.05 versus HG group. HG: high glucose; HSYA: hydroxysafflor yellow A; HUVEC: HG-induced human umbilical vein endothelial cell; ROS: reactive oxygen species; NOX4: NADPH oxidase 4.

Effect of HSYA on HG-induced NOX4 activation

The NOX4 expression levels were increased in the HG-treated HUVECs (Figure 7(c)). In addition, HSYA inhibited HG-induced NOX4 expression (Figure 7(c)). These data suggested that HSYA inhibits HG-induced ROS levels in HUVECs via the NOX4 pathway.

Discussion

HG is a key factor responsible for ECECs injury, which subsequently leads to the development of diabetes. In this study, we showed that HSYA protects ECs against both oxidative stress and apoptosis. Furthermore, HG induces the expression of CAMs and promotes hyperpermeability and cell adhesion. HG enhances the levels of VEGF and bFGF in vitro. Interestingly, HSYA reverses all of these deteriorating effects of HG. Then, the potential mechanism for HSYA reducing HG-mediated EC injury was investigated. HSYA reduces the expression of NOX4, which is a key regulator of ROS generation in ECs.^24,25 Our data demonstrated that HSYA reduces HG-mediated ROS and apoptosis via the NOX4 pathway. These results indicated that HSYA might have a beneficial effect on diabetes treatment.

HUVECs are regarded as an in vitro model for the investigation of the role of ECs.^26
–28 Therefore, HUVECs were used to detect the effect of HSYA on ECs in this study. Increased monocyte-EC adhesion has been demonstrated in diabetes models both in vivo and in vitro.²⁹ It also has been reported that HG enhances leukocyte adhesion to ECs via upregulation of CAMs. In addition, CAMs are involved in diabetes-associated vascular complication development.³⁰ Our results confirmed that the expression of VCAM-1, ICAM-1, and E-selectin increases in HG-treated HUVECs. Our data are consistent with previous findings indicating that HG is a potent inductor of leukocyte adhesion to ECs via upregulation of E-selectin, ICAM-1, and VCAM-1. Additionally, the adhesion of monocytes to the endothelium is a key event in the vascular inflammation process. In this study, HSYA prevented the expression of CAMs and the adhesion of HUVECs. Based on the current data, HSYA inhibits HG-increased EC disruption. The past results showed that HSYA could inhibit methylglyoxal-induced injury in cultured human brain microvascular endothelial cells, which was associated with its antiglycation effect.³¹ The in vitro data indicated that HSYA could increase both the angiogenesis and the keratinocyte migration. HSYA suppressed the nitric oxide production, demonstrating the anti-inflammatory role of HSYA. The in vivo data showed that HSYA improved the rate of wound closure. Furthermore, HSYA increased the collagen content, VEGF, and TGF-β1 expression. Therefore, HSYA should be considered a new therapeutic strategy in the treatment of diabetes.³²

VEGF is the most efficient cytokine for stimulating EC viability, and it has many biological effects including elevating vascular permeability and inflammatory responses.³³ bFGF is also related to inflammatory responses.³⁴ We found that HG reduces VEGF and bFGF, which is reversed by HSYA. These data suggested that HSYA decreases HG and triggers vascular permeability and inflammatory responses via reducing VEGF and bFGF levels. Therefore, HSYA may be used in vascular inflammatory disease treatment.

Previous studies have indicated that HG prompts oxidative stress and ROS generation.³⁵ We have detected the protective effect of HSYA on HG-induced cellular H₂O₂ concentrations and oxidative stress. HSYA mitigated HG-induced cellular H₂O₂ content and ROS in HUVECs. NOX4 is the key regulator in EC dysfunction.³⁶ We found that HG-induced ROS levels in HUVECs are reduced by DPI. Further, HG-induced HUVEC apoptosis is also reduced by DPI. The data suggested that NOX4 plays a key role in ROS generation and cell apoptosis induced by HG. In addition, HSYA inhibits HG-induced ROS levels in HUVECs via the NOX4 pathway.

In summary, our results demonstrated that HSYA has potent therapeutic benefits against HG-induced EC injury via attenuation of H₂O₂ and ROS generation, NOX4 activation, adhesion molecules and monocyte EC adhesion. Our findings indicated that HSYA may be considered as a potent agent for diabetic vascular inflammatory disease treatment. Although HYSA has various bioactivity effects, it is currently mainly used in cardiovascular and cerebrovascular disease treatment. More clinical and translational research studies are needed, especially for diabetic vascular inflammatory disease, as well as studies focusing on the molecular mechanisms of HYSA. Further research on the molecular mechanisms of HYSA is needed, and the number of clinical trials of HYSA needs to be increased.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Discipline Construction Project of Health and Family Planning Commission of Pudong New Area (nos. PWZxq2017-17, PWZxk2017-07, and PWZzb2017-22).

ORCID iD

S Chen

References

Flor

Baldoni

Aquino

. What is the association between social capital and diabetes mellitus? A systematic review. Diabetes Metab Syndr 2018; 12(4): 601–605.

Pelaez-Jaramillo

Cardenas-Mojica

Gaete

. Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment. Diabetes Ther 2018; 9(2): 521–543.

Semeraro

Cancarini

dell’Omo

. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res 2015; 2015: 582060.

Sena

Pereira

Seica

. Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013; 1832(12): 2216–2231.

Kovamees

Shemyakin

Checa

. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101(11): 3952–3958.

Leung

Phan

Leung

. Endothelial function and left ventricular diastolic functional reserve in type 2 diabetes mellitus. Open Heart 2014; 1(1): e000113.

Liang

Chen

Zheng

. The opening of ATP-sensitive K+ channels protects H9c2 cardiac cells against the high glucose-induced injury and inflammation by inhibiting the ROS-TLR4-necroptosis pathway. Cell Physiol Biochem 2017; 41(3): 1020–1034.

Lee

Ryu

Jung

. High glucose upregulates BACE1-mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells. Sci Rep 2016; 6: 36746.

Yan

Xun

. Activation of Na+/K+-ATPase attenuates high glucose-induced H9c2 cell apoptosis via suppressing ROS accumulation and MAPKs activities by DRm217. Acta Biochim Biophys Sin (Shanghai) 2016; 48(10): 883–893.

10.

Ying

. Resveratrol prevents ROS-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of AMPK/Sirt1/PGC-1alpha pathway. Oxid Med Cell Longev 2017; 2017: 7584691.

11.

Sun

Liu

Chen

. Curcumin attenuates high glucose-induced podocyte apoptosis by regulating functional connections between caveolin-1 phosphorylation and ROS. Acta Pharmacol Sin 2016; 37(5): 645–655.

12.

Liao

. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep 2015; 5: 12724.

13.

Jin

Sun

Zang

. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury. Chin J Integr Med 2016; 22(1): 36–41.

14.

Wang

Liu

Huang

. Activation of PPARγ is required for hydroxysafflor yellow A of Carthamus tinctorius to attenuate hepatic fibrosis induced by oxidative stress. Phytomedicine 2013; 20(7): 592–599.

15.

Zou

Wang

Liu

. Nucleolin mediated pro-angiogenic role of hydroxysafflor yellow A in ischaemic cardiac dysfunction: post-transcriptional regulation of VEGF-A and MMP-9. J Cell Mol Med 2018; 22(5): 2692–2705.

16.

Meselhy

Kadota

Momose

. Two new quinochalcone yellow pigments from Carthamus tinctorius and Ca2+ antagonistic activity of tinctormine. Chem Pharm Bull (Tokyo) 1993; 41(10): 1796–1802.

17.

Huber

Priest

Geisbuhler

. Cardioprotective effect of hydroxysafflor yellow A via the cardiac permeability transition pore. Planta Med 2017; 84(8): 507–518.

18.

Min

Wei

. Hydroxysafflor yellow A cardioprotection in ischemia-reperfusion (I/R) injury mainly via Akt/hexokinase II independent of ERK/GSK-3beta pathway. Biomed Pharmacother 2017; 87: 419–426.

19.

Sun

Qin

. Protective cerebrovascular effects of hydroxysafflor yellow A (HSYA) on ischemic stroke. Eur J Pharmacol 2018; 818: 604–609.

20.

Pei

Fan

Nan

. HSYA alleviates secondary neuronal death through attenuating oxidative stress, inflammatory response, and neural apoptosis in SD rat spinal cord compression injury. J Neuroinflammation 2017; 14(1): 97.

21.

Pan

Zhang

Zheng

. Hydroxysafflor yellow A suppresses MRC-5 cell activation induced by TGF-β1 by blocking TGF-β1 binding to TβRII. Front Pharmacol 2017; 8: 264.

22.

Yang

Zhu

. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. Eur J Pharmacol 2015; 754: 105–114.

23.

Guo

. Adiporedoxin suppresses endothelial activation via inhibiting MAPK and NF-κB signaling. Sci Rep 2016; 6: 38975.

24.

Kim

Tatsunami

. ROS-induced ROS release orchestrated by Nox4, Nox2, and mitochondria in VEGF signaling and angiogenesis. Am J Physiol Cell Physiol 2017; 312(6): C749–C764.

25.

Pendyala

Gorshkova

Usatyuk

. Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid Redox Signal 2009; 11(4): 747–764.

26.

Guo

Wei

. Dose-dependent effects of strontium ranelate on ovariectomy rat bone marrow mesenchymal stem cells and human umbilical vein endothelial cells. Int J Biol Sci 2016; 12(12): 1511–1522.

27.

Hirasawa

Kurita-Ochiai

. Porphyromonas gingivalis induces apoptosis and autophagy via ER stress in human umbilical vein endothelial cells. Mediators Inflamm 2018; 2018: 1967506.

28.

Song

Kang

Sun

. Crocetin inhibits lipopolysaccharide-induced inflammatory response in human umbilical vein endothelial cells. Cell Physiol Biochem 2016; 40(3-4): 443–452.

29.

Whetzel

Bolick

Srinivasan

. Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor. Circ Res 2006; 99(7): 731–739.

30.

Bae

. Vicenin-2 and scolymoside inhibit high-glucose-induced vascular inflammation in vitro and in vivo. Can J Physiol Pharmacol 2016; 94(3): 287–295.

31.

Liu

. Hydroxysafflor yellow A protects methylglyoxal-induced injury in the cultured human brain microvascular endothelial cells. Neurosci Lett 2013; 549: 146–150.

32.

Gao

Chang

Niu

. Topical application of hydroxysafflor yellow A accelerates the wound healing in streptozotocin induced T1DM rats. Eur J Pharmacol 2018; 823: 72–78.

33.

Pauty

Usuba

Cheng

. A vascular endothelial growth factor-dependent sprouting angiogenesis assay based on an in vitro human blood vessel model for the study of anti-angiogenic drugs. EBioMedicine 2018; 27: 225–236.

34.

Zittermann

Issekutz

. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J Leukoc Biol 2006; 80(2): 247–257.

35.

Lin

Wang

. GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells. Sci Rep 2017; 7(1): 8008.

36.

Ding

Zhang

. Luteolin inhibits smooth muscle cell migration and proliferation by attenuating the production of Nox4, p-Akt and VEGF in endothelial cells. Curr Pharm Biotechnol 2014; 14(12): 1009–1015.

Hydroxysafflor yellow A attenuates high glucose-induced human umbilical vein endothelial cell dysfunction

Abstract

Keywords

Introduction

Materials and methods

Chemicals and reagents

Cell culture and treatment

Cell viability

Annexin-V/FITC assay

Permeability assay

Levels of CAMs with an ELISA

HUVEC adhesion assay

H2O2 release assay

Intracellular ROS assay

Western blotting

VEGF and bFGF content in the cell culture supernatant by ELISA

Statistical analysis

Results

The effects of HSYA on HUVEC viability

HSYA attenuates HG-induced HUVEC apoptosis

Effects of HSYA on HG-induced disruption of the endothelial barrier function in HUVECs

Effects of HSYA on HG-enhanced CAM expression and THP-1 adhesion

Effects of HSYA on the level of VEGF and bFGF in the HG-treated HUVECs

Effect of HSYA on HG-induced oxidative stress

Effect of HG-induced ROS production by activating NOX4

Effect of HSYA on HG-induced NOX4 activation

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iD

References

H₂O₂ release assay